polatuzumab vedotin (Polivy)

following a reassessment under the end of life and orphan equivalent medicine process:

polatuzumab vedotin (Polivy®) is accepted for use within NHSScotland.

Indication under review: in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).

In a phase Ib/II study, polatuzumab vedotin in combination with bendamustine and rituximab resulted in an increase in complete response rate compared with bendamustine and rituximab alone.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

SMC previously accepted polatutuzumab for use in this indication on an interim basis (SMC2282). This supersedes that advice.